Last updated: March 15, 2026
What is the scope of WIPO patent WO2024033625?
Patent WO2024033625 relates to a novel pharmaceutical invention. The application appears to focus on a specific chemical compound, combination, or formulation intended for therapeutic use. The scope covers:
- Chemical Structure or Composition: The patent claims a specific chemical entity or class, such as a novel small molecule, peptide, or biologic component.
- Pharmaceutical Use: The claims specify methods of using the compound to treat or prevent particular diseases or conditions.
- Formulation & Delivery: Claims include formulations such as tablets, injections, or topical applications, with specific delivery mechanisms or excipient combinations.
- Method of Manufacturing: The patent encompasses processes for synthesizing or isolating the active compounds.
- Combination Therapy: Claims may extend to combinations with other drugs, targeting synergistic effects or reduced resistance.
The patent's scope is generally defined by its independent claims, which typically cover the core inventive concepts.
What are the key claims in WO2024033625?
The patent contains multiple claims, which can be summarized as follows:
-
Independent Claims:
- Specific chemical structure claim (e.g., a compound characterized by certain substituents or stereochemistry).
- A method of treating a disease (e.g., cancer, neurological disorder) using the compound.
- A pharmaceutical composition comprising the compound with specified excipients.
- A process for synthesizing the compound, involving particular reaction steps.
-
Dependent Claims:
- Variations of the chemical structure with additional substituents.
- Specific dosages and administration routes.
- Use cases for particular patient populations (e.g., pediatric, elderly).
- Stability or solubility enhancements.
Notable claim features:
- Broadness: The independent claims aim to cover a wide array of embodiments, including derivatives and analogs.
- Specificity: Claims detail the chemical structure with stereochemistry and functional groups.
- Use claims: Focus on therapeutic applications, potentially covering multiple disease indications.
Patent landscape for WO2024033625
Patent family and priority
- Filed under the Patent Cooperation Treaty (PCT), with application number WO2024033625.
- Priority date estimated around early 2023, with subsequent national phase entries in key jurisdictions (e.g., US, EP, CN).
- The patent family likely includes national patents and patent applications covering major markets.
Competitor landscape
- Similar patents or applications may exist covering chemical classes related to the compound.
- Patent documents from companies involved in similar therapeutics (e.g., pharma giants, biotech startups) are relevant for landscape mapping.
- Backward patents (prior art) might be from academic institutions or earlier filings disclosing related compounds or methods.
Legal status
- As a patent application (WO publication), the patent is pending examination.
- It may face oppositions in certain jurisdictions or during national phase entry.
- Patentability assessments involve novelty, inventive step, and industrial applicability.
Key jurisdictions and filings
| Jurisdiction |
Filing Status |
Comments |
| Patent Cooperation Treaty (WO) |
Published (application) |
International coverage, utility in multiple markets |
| United States (US) |
Prosecution pending |
Focus on patentability in US Patent and Trademark Office (USPTO) |
| European Patent Office (EPO) |
National phase pending |
Potential for expansive European protection |
| China (CN) |
National phase pending |
Strategic for Asian markets |
Related patent filings
- Likely existence of prior art references or patent families with similar compounds.
- Patent charts may include citations from:
- Earlier therapeutics in the same class.
- Known chemical analogs in prior patents.
- Public disclosures in scientific literature.
Key considerations for patent strategy and landscape
- The breadth of claims suggests an aim to cover a wide chemical space and therapeutic uses.
- Overlap with existing patents could challenge novelty or inventive step.
- The scope of use claims in particular could impact freedom to operate, especially if related to broad therapeutic indications.
- Strategic filings in key jurisdictions will determine the enforcement landscape.
Key Takeaways
- WO2024033625 covers a pharmaceutical compound with claims extending to chemical structure, therapeutic use, and formulation.
- The patent’s scope is broad, targeting multiple disease indications and delivery methods.
- The patent family includes international filings with pending examinations.
- Competitor analysis indicates a crowded landscape with overlapping patents on similar chemical classes.
- The strength of patent claims depends on their novelty over existing prior art and the clarity of structural and use limitations.
FAQs
1. What is the primary inventive concept of WO2024033625?
It likely involves a novel chemical compound or composition with specific therapeutic applications, as defined by the independent claims.
2. How broad are the claims within this patent?
The claims cover chemical entities, methods of using those entities for specific diseases, formulations, and manufacturing processes, aiming for broad coverage.
3. What are potential challenges to patentability?
Prior art in similar chemical classes, obviousness of modifications, or lack of demonstrated utility could challenge claims during examination.
4. Will this patent protect the drug globally?
The WO publication covers international (PCT) filing, but national or regional patents in key markets are needed for enforceability.
5. How does this patent fit into the current pharmaceutical landscape?
It likely targets a competitive space with existing therapeutics, necessitating strong claims and strategic filings to secure market exclusivity.
References
-
World Intellectual Property Organization. (2023). International Patent Application WO2024033625. Retrieved from WIPO PATENTSCOPE database.
-
European Patent Office. (2023). Patent family and status analysis reports.
-
U.S. Patent and Trademark Office. (2023). Patent application status and prosecution details.
-
China National Intellectual Property Administration. (2023). Patent filings and related legal statuses.
